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Abstract 
Motivation: The wealth of data resources on human phenotypes, risk factors, molecular traits and 
therapeutic interventions presents new opportunities for population health sciences. These opportuni-
ties are paralleled by a growing need for data integration, curation and mining to increase research 
efficiency, reduce mis-inference and ensure reproducible research. 
Results: We developed EpiGraphDB (https://epigraphdb.org/), a graph database containing an array 
of different biomedical and epidemiological relationships and an analytical platform to support their use 
in human population health data science. In addition, we present three case studies that illustrate the 
value of this platform. The first uses EpiGraphDB to evaluate potential pleiotropic relationships, ad-
dressing mis-inference in systematic causal analysis. In the second case study, we illustrate how pro-
tein-protein interaction data offer opportunities to identify new drug targets. The final case study inte-
grates causal inference using Mendelian randomization with relationships mined from the biomedical 
literature to “triangulate” evidence from different sources. 
Availability: The EpiGraphDB platform is openly available at https://epigraphdb.org. Code for replicating 
case study results is available at https://github.com/MRCIEU/epigraphdb as Jupyter notebooks using 
the API, and https://mrcieu.github.io/epigraphdb-r using the R package. 
Contact: yi6240.liu@bristol.ac.uk, ben.elsworth@bristol.ac.uk, Tom.Gaunt@bristol.ac.uk 
Supplementary information: Supplementary data are available at Bioinformatics online. 
 
 
1 Introduction  
The wealth and diversity of biomedical and population data now available 
to epidemiologists is enabling new discoveries and methods development 
in population health data science. However, harmonisation and integration 
of data presents a challenge to researchers aiming to “triangulate” evi-
dence from different sources or uncover potential mechanistic pathways 
of disease development. This challenge can be tackled through the devel-
opment of dedicated data integration platforms which curate and combine 
data sources to enable integrative analyses, taking this burden off of indi-
vidual researchers. 
One area in which data integration offers potential value is causal infer-
ence. Over the last two decades, Mendelian randomization (MR) (Davey 
Smith and Ebrahim, 2003) has risen to prominence as a key causal infer-
ence method. MR exploits genetic variants as causal “anchors” (randomly 
allocated and invariant from conception) to estimate causal effects be-
tween an “exposure” (risk factor) influenced by the genetic variant(s) and 
a health outcome. The approach has various assumptions, of which a key 
constraint is that the genetic variants should not pleiotropically affect the 
health outcome through a pathway other than the risk factor in question. 
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The two-sample MR approach enables MR to be performed in situations 
where a risk factor (exposure) and an outcome are analysed for genetic 
association in separate studies (Pierce and Burgess, 2013), enabling the 
thousands of published genome-wide association study (GWAS) datasets 
(MacArthur et al., 2016) to be leveraged for causal inference. 
Database resources such as the IEU OpenGWAS database 
(https://gwas.mrcieu.ac.uk) (Elsworth, Lyon, et al., 2020), and the linked 
MR-Base analytical platform (Hemani et al., 2018) now enable systematic 
MR application using the MR Mixture of Experts approach (Hemani et 
al., 2017). Such “systems” approach offers the capacity to standardise the 
evaluation of potential intervention targets, as we have recently demon-
strated with the plasma proteome (Zheng, Haberland, et al., 2019). How-
ever, such throughput approaches raise new challenges in the interpreta-
tion of the wealth of causal estimates generated. The integration of causal 
estimates with data from other sources is one way to tackle such chal-
lenges. Combining evidence with different biases (such as MR estimates, 
observational correlations and literature-mined experimental results) can 
provide more robust causal interpretation in an approach described as “tri-
angulation” (Lawlor et al., 2017). Agreement between sources strengthens 
the case for causality, whilst disagreement helps identify sources of bias. 
Integration of data also offers the scope to gain more mechanistic in-
sight into complex networks of association. For example, linking pheno-
typic data with genetic variants and molecular pathway data may make it 
easier to identify potential intervention targets once a causal relationship 
has been established. Similarly, an extensive network of associations pro-
vides the opportunity to identify drug repositioning opportunities and on-
target side effects for pharmaceutical targets. 
Here we describe EpiGraphDB (https://epigraphdb.org/), a database 
and analytical platform, that integrates trait relationships (causal, observa-
tional or genetic), literature-mined relationships, biological pathways, pro-
tein-protein interactions, drug-target relationships and other data sources 
to support data mining of risk factor/disease relationships. In the following 
sections, we describe the EpiGraphDB platform and its epidemiological 
and biomedical resources, and then illustrate some potential applications 
of this platform through specific case studies. 
2 Implementation 
2.1 The EpiGraphDB platform 
The EpiGraphDB platform (Figure 1) integrates data from a range of bi-
oinformatics and epidemiological sources into a Neo4j graph database 
and supports interactive and programmatic access using a variety of 
methods aimed at different needs. We provide a web user interface (UI) 
as a user-friendly entry point to the rich integrated resources that the 
platform offers, and users are able to programmatically query data via 
the application programming interface (API) web service or the client 
package in R. Finally, the Neo4j graph database can be directly queried 
in Cypher, and users are able to do so based on the Cypher examples 
shown from the API queries. 
Interactive access: As an entry point to the platform, the Web UI serves 
two primary purposes: 1) it showcases a selection of exemplar topics for 
the integrated epidemiological evidence that EpiGraphDB provides; 2) as 
an interactive interface it helps users in understanding how the queries of 
their requested data are structured to assist their further use of 
  
1 The getting started guide using Jupyter notebook can be found at 
(TODO) and the guide using the R package can be found at 
EpiGraphDB. For example, the confounder topic view 
https://epigraphdb.org/confounder demonstrates the use of EpiGraphDB 
in investigating the potential confounders, mediators and colliders be-
tween exposures and outcomes. In addition to viewing the returned data 
in tabular format and its visualisation in network diagrams, from the 
"Query" tab users are able to see the underlying API call and Neo4j Cy-
pher query to assist their further use of EpiGraphDB. In addition, users 
can use the Explore views https://epigraphdb.org/explore to browse and 
search EpiGraphDB and visit the Gallery https://epigraphdb.org/gallery 
for exemplar use cases. 
Programmatic access: EpiGraphDB can be queried via the API web 
service https://api.epigraphdb.org which includes a variety of accessible 
topic endpoints (as showcased on the Web UI) and other functionalities 
that enable further customised usage. In addition, we developed an R pack-
age https://mrcieu.github.io/epigraphdb-r to provide further ease of use for 
users to incorporate EpiGraphDB directly into their analytical pipelines in 
R, without having to be proficient in handling web requests or parsing 
response data. We discuss simple examples on how to query EpiGraphDB 
via the API or the R package in Appendix 4 in the supplementary materi-
als, and further details on accessing EpiGraphDB are available in the plat-
form documentation https://docs.epigraphdb.org. In addition, we provide 
companion guides on replicating results of the Section 3 case studies in 
Jupyter notebooks and R package vignettes as well as a "getting started" 
guide1 on accessing EpiGraphDB data programmatically. 
Graph database: At its core, EpiGraphDB stores integrated data using 
the Neo4j graph database. The graph database paradigm supports inter-
pretable representation of biomedical information by storing data as rela-
tionships (e.g. associations, causal estimates, mappings) between entities 
(e.g. genes, proteins, diseases, genetic variants). Compared to a relational 
database architecture using structured query language (SQL), the use of 
Neo4j and the associated Cypher query language enables more natural rep-
resentation of hypothesis as queries. For example, in EpiGraphDB a hy-
pothetical query for the causal effect for a risk factor on disease could be 
conceptualised in Cypher as a directed acyclic graph (DAG) (r:Risk-
Factor)-[c:CausalEffect]->(d:Disease), which as is an exact 
representation of the epidemiological modelling. Although users are not 
https://mrcieu.github.io/epigraphdb-r/articles/getting-started-with-
epigraphdb-r.html 
Fig. 1. Architecture of the EpiGraphDB platform. Source datasets are integrated into 
a Neo4j graph database using Cypher query language (which can also be queried by end 
users). Standard HTTP queries are processed through a RESTful API service which can 
be called from any REST API client, including our R package epigraphdb. The web UI 
showcases main topics of the epidemiological evidence in EpiGraphDB and demon-
strates the example API queries to get the underlying data. 
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required to know Cypher in order to use EpiGraphDB, the underlying Cy-
pher query that is used to return user's requested data via the Web UI, API, 
or R package is returned as part of the response data, which can be further 
used as a baseline query for users to customise for their specific needs. 
Discussions on accessing EpiGraphDB in Cypher using the API and R 
package are available in Appendix 4 in the supplementary materials. 
2.2 Integration of epidemiological evidence 
EpiGraphDB contains data from a range of biomedical sources, with these 
data represented as nodes and relationships2 in a graph database. The re-
lationships broadly represent: epidemiological relationships (e.g. genetic 
correlations) between phenotypes, mappings (e.g. genes to protein and 
pathways) and relationships derived from the biomedical literature. Table 
1 reports a summary of the epidemiological evidence available in 
EpiGraphDB. 
We combined data from over 20 independent sources. All datasets re-
quired some level of processing in preparation for loading into 
EpiGraphDB. Detailed information including sources of data, processing 
steps and data ingest method are described in the supplementary materials 
(Appendix 2) and further in the platform documentation 
https://docs.epigraphdb.org.  
Table 1. Summary of epidemiological evidence in EpiGraphDB. De-
tailed discussion on data integration and how these biomedical entities 
and associations are represented in EpiGraphDB are available in the sup-
plementary materials (Appendices 1 and 2). 
Cate-
gory 
Description Sources 
Causal 
relation-
ships 
Pairwise MR between 
traits 
MR-EvE (Hemani et al., 
2017) 
pQTL / eQTL MR 
xQTL (Zheng, Brumpton, 
et al., 2019) 
Associa-
tion rela-
tionships 
Genetic correlations 
Neale Lab (Abbot et al., 
2020) 
Observational correlations EpiGraphDB inhouse3 
GWAS top hits 
OpenGWAS (Elsworth, 
Lyon, et al., 2020) 
Polygenic risk score asso-
ciations 
PRS Atlas (Richardson et 
al., 2019) 
Protein-protein interac-
tions 
IntAct (Orchard et al., 
2014), STRING (Szklar-
czyk et al., 2019) 
Drug targets 
Open Targets (Carvalho-
Silva et al., 2019), CPIC 
(Relling and Klein, 2011), 
Druggable genome (Finan 
et al., 2017) 
Pathway ontologies and 
molecular events 
Reactome (Jassal et al., 
2019) 
  
2 We refer to a type of biomedical entity as a meta node (e.g. (Gwas) in 
Cypher notation) and a type of association as a meta relationship (e.g. 
[MR]), whereas a specific entity is referred to as a node (e.g. (Gwas 
{id: “ieu-a-2”, trait: “Body mass index”})) and a specific 
association as a relationship (e.g. (Gwas {trait: “Body mass in-
dex”})-[MR {beta, se, pval}]->(Gwas {trait: “Coronary 
heart disease”})). 
Molecu-
lar path-
ways 
Gene expression for tissues 
GTEx (The GTEx Consor-
tium et al., 2015) 
Litera-
ture 
mined / 
derived 
evidence 
Literature evidence of bio-
medical entities and mech-
anisms 
SemMedDB (Kilicoglu et 
al., 2012), MELODI (Els-
worth et al., 2018), Met-
aMap (Demner-Fushman 
et al., 2017), Monarch 
(Mungall et al., 2017) 
Mapping of biomedical en-
tities to literature terms 
Ontol-
ogy and 
semantic 
relation-
ships 
Mapping of biomedical en-
tities to ontology terms 
EFO (Malone et al., 2010), 
SemMedDB (Kilicoglu et 
al., 2012), Vectology (Els-
worth, Liu, et al., 2020), 
MELODI (Elsworth et al., 
2018),  
Semantic similarities of bi-
omedical entities 
Vectology (Elsworth, Liu, 
et al., 2020) 
Entity 
metrics4  
Meta 
nodes 
Meta rela-
tionships 
Nodes Relation-
ships 
14 42 32,969,103 84,181,124 
3 Case studies 
The data integrated within EpiGraphDB offer a wide array of potential 
opportunities for data mining and analysis. Here we present three case 
studies which illustrate some of the potential that is afforded by 
EpiGraphDB for new knowledge discovery. These do not, however, rep-
resent the full extent of the data or potential of the platform, which is pro-
vided as an open resource for the reader to use for their own novel research 
investigations. 
In case study 1 we explore the potential of pathway data to characterise 
pleiotropy of genetic instruments used to generate causal estimates of the 
effect of protein levels on disease outcomes. Case study 2 seeks to identify 
alternative drug targets using protein-protein interaction data in conjunc-
tion with causal estimates of protein levels on disease outcomes as well as 
literature mined / derived evidence. Case study 3 uses knowledge ex-
tracted from the scientific literature to identify potential mechanistic path-
ways linking causal risk factors to diseases. We discuss the general steps 
to replicate these case studies in Appendix 5 in the supplementary materi-
als and users are encouraged to use the Jupyter notebooks and R package 
to replicate and modify the analyses. 
3.1 Distinguishing vertical and horizontal pleiotropy 
for SNP-protein associations 
A key MR assumption is that the genetic variant (SNP) is only related to 
the outcome of interest through the exposure under study (the “exclusion 
restriction” assumption). This assumption is potentially violated under 
horizontal pleiotropy, where a SNP is associated with multiple pheno-
types (e.g. proteins) independently of the exposure of interest. In con-
3 Further details on the inhouse results by EpiGraphDB members are 
available from Appendix 2 in the supplementary materials. 
4 Information and metrics are based on latest version of EpiGraphDB 
platform (version 0.3.0, 21 April 2020). 
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trast, vertical pleiotropy, where a SNP is associated with multiple pheno-
types on the causal pathway to the outcome, does not violate the “exclu-
sion restriction criterion” of MR (Figure 2A). For molecular phenotypes, 
where the number of genetic instruments is typically limited, it is almost 
impossible to distinguish vertical and horizontal pleiotropy using estab-
lished statistical approaches (van Kippersluis and Rietveld, 2018). 
Here, by integrating SNP-protein associations with biological pathway 
and protein-protein interaction (PPI) information retrieved from 
EpiGraphDB, we have developed an approach to assess potential horizon-
tal pleiotropy. As demonstrated in Figure 2B, for a SNP associated with a 
group of proteins, we check the number of biological pathways and PPIs 
that are shared across this group of proteins. If these proteins are mapped 
to the same biological pathway and/or a PPI exists between them, then the 
SNP is more likely to act through vertical pleiotropy and therefore be a 
valid instrument for MR. 
3.1.1 Assessing the pleiotropy of an autoimmune-related variant 
In this case study, we assessed the pleiotropy of rs12720356, a SNP lo-
cated in TYK2 gene that is associated with Crohn’s disease and psoriasis 
(Solovieff et al., 2013), by exploring the relationships between genes (and 
their products) to which this SNP can be mapped using expression QTL 
data. We used the GTEx database (The GTEx Consortium et al., 2015) to 
identify single-tissue eQTL effects, gathering a set of genes whose expres-
sion level is associated with rs12720356 in different tissues: FDX1L, 
ICAM1, ICAM5, KRI1, MRPL4, GRAP2, TMED1, TYK2 and ZGLP5. 
We then proceeded to query EpiGraphDB to extract pathway and PPI data 
as described in the methods section. 
The results were then converted to a graph that shows two small con-
nected components and a few isolated nodes (Figure 3). Note that the 
knowledge about the biological processes described by pathways have to 
be considered incomplete, and perhaps partially incorrect, and therefore 
these results must be treated as hypothesis generating, and the user should 
be aware that absence of interaction evidence is not definitive proof of an 
absence of pleiotropy. Also, given that the same protein might participate 
  
5 Details on the list of pleiotropic genes are reported in Supplementary 
Table 4. 
in different pathways in different contexts, it is important to verify the 
soundness of these relationships. For instance, in our case study ICAM1 
shares pathways with ICAM5, the interactions of integrin cell surface and 
between lymphoid and non-lymphoid cells. Integrin expression has been 
shown to be altered in psoriasis (Creamer et al., 1995), and integrins also 
have an important pro-inflammatory role in Crohn's disease, where they 
facilitate the movement of leukocytes from the systemic circulation (note 
that the association is detected in whole blood) to the intestinal mucosa 
(Park and Jeen, 2018). ICAM1 also participates with TYK2 in the regula-
tion of Interleukin-4 (IL4) and Interleukin-13 (IL3) signalling, important 
actors that drive a predominantly humorally mediated hypersensitivity re-
sponse (Sartor, 1994). In terms of PPIs, the above pairs of genes are still 
connected, and we retrieved a triple formed by ICAM1, RAVER1 and 
TYK2, and the pair KRI1-MRPL4 that is associated with sun exposure, a 
well-established beneficial factor for psoriasis and Crohn’s disease (Søy-
land et al., 2011; Jantchou et al., 2014). However, here the results depict 
that some single-tissue eQTLs with a strong association, like ZGLP1 and 
FDX2, remain unconnected in our network. This shows that they poten-
tially work along different molecular pathways, acting in horizontal plei-
otropy. It would be important to consider their potential biological role in 
the outcome phenotypes of any MR analyses using this instrument. 
3.1.2 An exemplar valid instrument 
We recently used the same approach to explore potential vertical and hor-
izontal pleiotropy for a number of pleiotropic protein associated SNPs 
(Zheng, Haberland, et al., 2019). In one example, a specific set of three 
proteins (IL6ST, ICAM1 and TIMP1) were associated with the same SNP 
(rs144276707). The pair ICAM1 and TIMP1 were found to participate in 
two common pathways, and there were 4 shared PPIs among all three pro-
teins. These results supported the hypothesis that rs144276707 is more 
likely to influence these proteins via the same biological pathway (acting 
through vertical pleiotropy), strengthening the evidence that this SNP is a 
valid instrument for MR analysis. 
3.2 Identification of potential drug targets 
Fig. 2. Distinguishing vertical and horizontal pleiotropy using EpiGraphDB. (A) 
Concept of vertical and horizontal pleiotropy using SNP-proteins relationship as an exam-
ple. We have a valid instrument for MR when a SNP affects proteins in a single path; in 
contrast, if an instrument is associated with proteins participating in different pathways, it 
violates the “exclusion restriction criterion” and our instrument is invalid. (B) Integration 
of SNP-protein associations with pathway information and PPI data to distinguish vertical 
and horizontal pleiotropy using EpiGraphDB. All four proteins are associated with the 
same SNP. Protein 1 and protein 2 share the same biological pathway. Protein 2 and 3 are 
in PPI. Protein 4 shares no links with other proteins. Therefore, the SNP association on 
protein 1, 2 and 3 are likely to act through vertical pleiotropy, where the SNP association 
on protein 4 verse other three proteins are likely to be horizontal pleiotropy. 
Fig. 3. Network diagram with the evidence to assess the pleiotropy of genetic vari-
ant rs12720356. The network has one node for each protein regulated by the eQTL 
rs12720356, and their size is inversely proportional to their P-value (see Supplementary 
Table 4 for details). Dashed pink edges depict the participation in common biological 
pathways, and blue edges represent the number of shared PPIs (value indicated). 
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Systematic MR of molecular phenotypes, such as proteins and levels of 
transcript expression, opens up important possibilities for drug target pri-
oritisation in pharmacological investigations. However, many potential 
targets are not easily druggable. A parallel problem is that current GWAS 
of plasma proteins have limited sample sizes, are not available in many 
tissues, and only represent a subset of all proteins. A potential way to ad-
dress these problems is to use protein-protein interaction (PPI) infor-
mation to identify druggable targets linked to a non-druggable, but ro-
bustly causal gene. Their relationship to the causal gene increases our con-
fidence in their potential causal role even if the initial evidence of their 
causal effect is below our multiple-testing threshold. Here we have devel-
oped an approach using PPI data to prioritise potential alternative drug 
targets. As a proof of principle, we illustrate this approach using IL23R as 
an example. 
3.2.1 Integrating MR evidence with PPI networks for alternative 
drug targets search 
IL23R is a well-established disease-susceptibility gene for inflammatory 
bowel disease (IBD) (de Lange et al., 2017). The protein-disease associa-
tion information retrieved from EpiGraphDB suggests that IL23R has a 
robust causal effect on IBD6 (beta = 1.50, P-value = 2.21 × 10-166, colo-
calization probability = 75%) (Zheng, Haberland, et al., 2019). The drug 
PTG-200, acting as an antagonist of IL23R has just passed Phase I and is 
in Phase II trials for IBD treatment (Cheng et al., 2019), which aligns well 
with the genetic/MR evidence implemented in EpiGraphDB. Whilst 
IL23R is druggable, we illustrate how our approach can identify potential 
alternative targets using pathway data. 
We used PPI information (Orchard et al., 2014; Szklarczyk et al., 2019) 
and data on druggability (Finan et al., 2017) to identify a set of proteins 
which are the target of approved drugs and clinical-phase drug candidates 
and have direct PPI with IL23R. Table 2 shows a subset of this list with 
strong MR evidence (P-value < 1 × 10-5) to IBD7. 
This list of proteins includes IL12B, the target protein for an existing 
drug Ustekinumab, which is currently under Phase 3 and 4 trials for IBD 
treatment8. Although there is strong MR evidence for IL12B (beta = 0.42, 
P-value = 9.59 × 10-34), there is little evidence for genetic colocalization9 
(colocalization probability < 1%), which prevents us prioritizing this tar-
get based on MR evidence alone. However, the PPI between IL12B and 
IL23R (which does have reliable MR and colocalization results) increases 
our confidence that IL12B is a valid target. 
3.2.2 Using literature evidence for results enrichment and triangu-
lation 
A further source of useful evidence is the literature-derived knowledge 
from SemMedDB (Kilicoglu et al., 2012) available in EpiGraphDB. Inte-
grating this literature evidence with the evidence described above can fur-
ther enhance confidence in the findings (as well as identify potential alter-
native drug targets). Table 2 also reports the gene-to-trait literature evi-
dence regarding IL23R and interacting proteins and IBD, where each entry 
shows a literature-derived semantic triple (e.g. “IL23R” – 
“ASSOCIATED_WITH” – “Inflammatory Bowel Diseases”), as well as 
the study articles from which each triple was extracted. For the list of 
genes including IL23R and IL12B that were identified with strong MR 
  
6 https://epigraphdb.org/pqtl/IL23R 
7 Supplementary Table 5 reports the full list of identified proteins with 
druggability information. 
evidence, we were also able to find abundant literature evidence support-
ing the genetic causal evidence with derived mechanisms involving pred-
icates such as ASSOCIATED_WITH, AFFECTS and CAUSES. 
Table 2. Triangulation of MR and literature evidence on the effects 
of IL23R and associated genes to IBD. The MR evidence is the QTL 
MR estimates of IL23R and the associated druggable genes (via direct 
protein-protein interaction with Tier 1 druggability) to Inflammatory 
bowel disease GWAS (OpenGWAS ID: ieu-a-249). The literature evi-
dence is the SemMed predicates derived by SemMedDB and the num-
bers of PubMed articles identified to support the predicate mechanism. 
Here we report the subset of genes that are identified to contain both MR 
evidence (P-value < 1 × 10-5). 
Gene 
Effect 
size 
(SE) 
P-value QTL 
SemMed predicate 
(count) 
IL23R 
1.50 
(0.05) 
2.21 × 10-
166 
pQTL 
AFFECTS (1), 
ASSOCIATED_WITH 
(21), 
NEG_ASSOCIATED_
WITH (2), 
PREDISPOSES (1) 
0.89 
(0.06) 
4.16 × 10-
43 
eQTL 
IL12B 
0.42 
(0.03) 
9.59 × 10-
34 
pQTL 
ASSOCIATED_WITH 
(5) 
IL15 
-1.42 
(0.20) 
5.53 × 10-
13 
eQTL 
ASSOCIATED_WITH 
(2) 
IL4 
0.46 
(0.08) 
4.47 × 10-
08 
eQTL 
ASSOCIATED_WITH 
(3), DISRUPTS (1) 
JAK2 
-1.90 
(0.20) 
1.32 × 10-
20 
eQTL 
AFFECTS (1), 
ASSOCIATED_WITH 
(3) 
NFKB1 
0.97 
(0.17) 
2.16 × 10-
08 
eQTL 
ASSOCIATED_WITH 
(2) 
RORC 
-1.00 
(0.12) 
1.21 × 10-
17 
eQTL 
ASSOCIATED_WITH 
(1) 
STAT3 
0.60 
(0.08) 
2.96 × 10-
15 
eQTL 
AFFECTS (2), 
AUGMENTS (1), 
ASSOCIATED_WITH 
(9), CAUSES (1) 
3.3 Triangulating causal estimates with literature evi-
dence 
Previously, we have demonstrated that existing literature can be used to 
derive relationships and mechanisms between defined biomedical traits 
(Elsworth et al., 2018; Elsworth and Gaunt, 2020). By integrating this 
knowledge with causal estimates in EpiGraphDB, we can triangulate evi-
dence, identifying where these two sources of evidence are in agreement, 
and where they are not (Lawlor et al., 2017). In this case study, we explore 
the literature connecting traits with pre-defined causal relationships. From 
here we can summarise the key mechanisms defined in the literature, and 
also potentially derive novel mechanisms. 
3.3.1 Sleep duration and coronary heart disease as an example 
8 Drug trial information available via Open Targets https://www.target-
validation.org/evi-
dence/ENSG00000113302/EFO_0000540?view=sec:known_drug 
9 http://epigraphdb.org/pqtl/IL12B 
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Starting with an exposure trait of “Sleep duration”, existing MR data, and 
connections between traits and diseases in EpiGraphDB, we extracted a 
set of potentially causally related traits (note that this is limited to traits 
with GWAS and MR results) (Table 3). 
Table 3. Summary of disease traits identified with causal association 
to “Sleep duration”. We searched for MR evidence associated with the 
trait “Sleep duration” with P-value to be under 1 × 10-10, and map the 
outcome trait to a disease term via mappings through EFO terms. “ieu-a-
“/  “ukb-a-“ refer to IDs of OpenGWAS . 
Exposure Outcome 
MR 
beta 
MR P-
value 
Disease 
ieu-a-1088: 
Sleep dura-
tion 
ukb-a-107: 
Non-cancer 
illness code 
self-re-
ported: gout 
-
0.00257 
3.8 × 
10-24 
“gout” 
ieu-a-1088: 
Sleep dura-
tion 
ieu-a-6: Cor-
onary heart 
disease 
-
1.03933 
2.3 × 
10-21 
“coronary ar-
tery disease” 
ieu-a-1088: 
Sleep dura-
tion 
ukb-a-548: 
Diagnoses - 
main 
ICD10: K35 
Acute ap-
pendicitis 
-
0.00671 
8.0 × 
10-15 
“appendicitis” 
ieu-a-1088: 
Sleep dura-
tion 
ukb-a-54: 
Cancer code 
self-re-
ported: lung 
cancer 
-
0.00191 
1.1 × 
10-14 “cancer”, 
“lung carci-
noma” 
ukb-a-9: 
Sleep dura-
tion 
ukb-a-13: 
Sleepless-
ness / in-
somnia 
-
0.32167 
1.1 × 
10-11 “insomnia 
(disease)” 
 
Multiple disease entries arise from the mapping between the trait name 
and EFO terms, each of which maps to a disease term. In this case, we 
treated each mapping as a single relationship and extracted the literature 
data connecting a pair of traits. For this example, we selected the outcome 
trait “Coronary heart disease” to explore in more detail the potential mech-
anisms linking this to sleep duration. To do this we queried EpiGraphDB 
to extract the semantic triples associated with each trait and searched for 
overlapping terms, identifying 839 overlapping triples (Supplementary 
Table 6 reports the top 10 items by enrichment P-value). 
We then generated frequency counts for the overlapping terms (Figure 
4), which identified many different overlapping terms and types10, includ-
ing 6 proteins (aapp), 2 genes (gngm) and 11 organic chemicals (orch). 
Each of these represents a key point in a potential mechanism, connecting 
the exposure and outcome traits. Terms of particular interest are those with 
high counts (e.g. Ethanol) as these represent terms with large numbers of 
supporting publications in the literature. However, in this case, Ethanol 
may be present in such numbers due to its inclusion in many publications 
as a co-factor when describing the functionality and efficacy of drugs, 
  
10 https://mmtx.nlm.nih.gov/MMTx/semanticTypes.shtml 
highlighting the importance of reviewing a selection of papers underpin-
ning each mechanism. For this reason, Ethanol can be excluded from this 
example.  
Figure 5 suggests the main route from Sleep Duration to Coronary Heart 
Disease via the intermediate term Leptin involves only one term on the 
Fig. 4. Literature-mined/derived evidence on the intermediates between “Sleep dura-
tion” and “Coronary heart disease”. Counts of overlapping SemMed terms grouped by 
the SemMed term type (aapp – amino acids, peptides, proteins, gngm – genes or genome, 
horm – hormones, orch – organic chemicals; full list available at 
https://mmtx.nlm.nih.gov/MMTx/semanticTypes.shtml ). 
Fig. 5. Literature derived mechanisms between “Sleep duration”, “Leptin”, and 
“Coronary Heart Disease”. Network diagram displaying the literature connections be-
tween “Sleep Duration” and “Coronary Heart Disease” through the intermediate term 
“Leptin”. Predicates connecting two semantic terms, their frequencies and enrichment P-
value are labelled on the edges. Enrichment is calculated via MELODI Presto (Elsworth 
and Gaunt, 2020) based on a comparison of query count to background. Edge width repre-
sents the enrichment log transformed P-value. Red nodes represent the exposure (SLEEP 
DURATION) and outcome (CORONARY HEART DISEASE) traits, blue nodes repre-
sent intermediate semantic literature nodes. 
EpiGraphDB 
exposure side (“ghrelin”) and 10 on the outcome side, the most enriched 
being “Leptin – TREATS - Coronary Arteriosclerosis”, providing this as 
a potential mechanism of interest. 
3.3.2 Check findings against the original publication text 
Finally, EpiGraphDB provides a PubMed identifier to enable us to check 
the validity of these connections in the original text. For example, we 
found evidence of two statements that “Leptin PREDISPOSES Coronary 
heart disease”. These were derived from the following two sentences: 
“CONCLUSIONS: Consumption of sugar-sweetened bever-
ages was associated with increased risk of CHD and some ad-
verse changes in lipids, inflammatory factors, and leptin.” (de 
Koning et al., 2012) 
“Leptin, one of the earlier adipocytokines, is known to play a 
major role in cardiovascular disease and recent observations 
suggest that leptin is an independent risk factor for coronary 
heart disease.” (Amasyali et al., 2010) 
The contrasting causal interpretation of these two sentences highlights 
the importance of manual review of the original articles to validate the 
semantic triples. 
4 Discussion 
EpiGraphDB is a new database and platform for data integration in health 
data science, with a particular focus on understanding the relationships 
between risk factors, intermediate phenotypes and disease outcomes de-
scribed by epidemiological analyses. Whilst we present three specific case 
studies, we anticipate a much wider array of uses and support this through 
an open API and R package. It is, however, important to recognise that 
there are several existing platforms for data integration in the health, bio-
medical and pharmaceutical domains (Supplementary Table 3).  
The Open Targets platform (Koscielny et al., 2017; Carvalho-Silva et 
al., 2019) (https://www.targetvalidation.org/) integrates a wealth of ge-
nomic, phenotypic, ontology and drug target data into a single platform 
aimed at users in the pharmaceutical industry and research community. 
Their platform has a well-developed web interface in addition to a com-
prehensive API and Python package to support the use of the API. This 
open approach has enabled EpiGraphDB to utilise drug/target mappings 
with Open Targets. However, whilst there is some overlap in this context, 
the Open Targets platform lacks MR estimates (although it does include 
genetic association data). Open Targets also includes some literature data, 
and their LINK platform (https://link.opentargets.io/) extracts semantic re-
lationships from PubMed. However, despite some of the conceptual simi-
larities to EpiGraphDB, their focus is primarily on drug target prioritisa-
tion, whilst EpiGraphDB also aims to support the evaluation of lifestyle 
risk factors. 
The Hetionet platform (https://het.io/) is a graph database integrating 
data from more than 29 different databases, which was initially set up to 
prioritize drugs for repurposing using an innovative approach to predict 
gene/disease associations (“Project Rephetio”) (Himmelstein and Baran-
zini, 2015; Himmelstein et al., 2017), but now aims to have a broader re-
mit. The platform is very accessible, with a web application, data down-
loads in multiple formats and open access to their Neo4j database. The 
primary focus of the platform is for molecular mechanisms and pharma-
cologic data while EpiGraphDB additionally encompasses epidemiologi-
cal relationships (MR causal estimates, genetic correlation, etc) and liter-
ature data. However, the open nature of the platform enables users to eas-
ily work with Hetionet in parallel with EpiGraphDB. 
The Monarch Initiative (Mungall et al., 2017) 
(https://monarchinitiative.org/) is focused on the integration of genotypic 
and phenotypic data across species with the aim of identifying related phe-
notypes and potential animal models of disease. This contrasts with the 
human-centric epidemiological focus of EpiGraphDB. The Monarch Ini-
tiative platform has an open-source approach to software development and 
offers web interfaces powered by an open API. In common with Hetionet 
and EpiGraphDB, the platform uses the Neo4j database. Users can easily 
integrate data from the Monarch Initiative with EpiGraphDB given their 
open design principles. 
Wikidata (https://wikidata.org) is a general knowledge base which con-
tains an array of biomedical data sources that have recently been reported 
(Waagmeester et al., 2020). In contrast to curated knowledge bases such 
as EpiGraphDB, Wikidata is developed through community-driven efforts 
and bot automation, and incorporates extensive knowledge across a wide 
array of fields, including (but not limited to) a range of biomedical entities. 
Unfortunately, the scope of this project leads to inevitable duplication and 
redundancy of the entities it comprises. This much broader approach dis-
tinguishes Wikidata from specialist platforms such as EpiGraphDB, which 
is focused on epidemiological and biomedical knowledge. In common 
with other platforms listed above, the open design of this platform sup-
ports cross-platform data integration. 
Various other platforms (Gaspar et al., 2018; Coker et al., 2019; Abbot 
et al., 2020) exist with some conceptual overlaps with EpiGraphDB (Sup-
plementary Table 3). These represent a range of different types of data 
based on molecular and genetic interactions and drug targets. However, in 
contrast to the platforms described above these platforms don’t appear to 
have accessible API or software packages. Although several are open ac-
cess and available to the wider community, the lack of programmatic in-
teroperability limits their scope. 
As with all similar platforms, EpiGraphDB is constrained by the avail-
able data and subject to any errors or quality issues that exist in the original 
sources. However, by integrating data from a range of sources (e.g. 
STRING, IntAct and Reactome for interactions between proteins) we en-
sure the user can evaluate consistency between data sources. 
5 Conclusions 
The EpiGraphDB platform provides an integrated data resource to support 
data mining and interpretation of the relationships between disease risk 
factors, intervention targets and disease outcomes. We present three illus-
trative case studies that demonstrate the functionality and utility of the 
platform, but it is important to note that much more extensive capabilities 
are available and will continue to expand as the platform is developed fur-
ther. We aim to support open science by making the data freely accessible, 
both programmatically and through a web interface, and by providing 
open source code and exemplar Jupyter notebooks. 
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